OraSure Technologies (NASDAQ:OSUR) Posts Earnings Results, Misses Estimates By $0.08 EPS

Key Points

• OraSure Technologies reported a quarterly loss of ($0.23) earnings per share (EPS), missing analysts' expectations of ($0.15) by ($0.08).
• The company's stock price remained flat at $3.12, with a market capitalization of $233.38 million and a price-to-earnings ratio of -7.43.
• Several institutional investors, including Amundi and Envestnet Asset Management, have recently increased their stakes in OraSure Technologies, with institutional ownership now at 93.50%.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) released its quarterly earnings results on Tuesday. The medical instruments supplier reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.08), Zacks reports. OraSure Technologies had a negative net margin of 36.84% and a negative return on equity of 10.81%. The firm had revenue of $31.24 million for the quarter, compared to the consensus estimate of $30.52 million. OraSure Technologies updated its Q3 2025 guidance to EPS.

OraSure Technologies Stock Performance

Shares of NASDAQ OSUR traded up $0.01 during midday trading on Friday, reaching $2.76. The stock had a trading volume of 256,352 shares, compared to its average volume of 773,136. The company has a market capitalization of $206.07 million, a price-to-earnings ratio of -4.11 and a beta of 0.27. OraSure Technologies has a 12-month low of $2.36 and a 12-month high of $4.61. The stock has a 50-day moving average of $3.05 and a 200-day moving average of $3.21.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Wall Street Zen upgraded OraSure Technologies from a "sell" rating to a "hold" rating in a research report on Saturday, May 17th. Evercore ISI reaffirmed an "in-line" rating and set a $3.00 price objective on shares of OraSure Technologies in a research report on Monday, May 19th.

Institutional Investors Weigh In On OraSure Technologies

A number of institutional investors have recently bought and sold shares of OSUR. Geode Capital Management LLC boosted its stake in shares of OraSure Technologies by 6.4% in the second quarter. Geode Capital Management LLC now owns 1,869,868 shares of the medical instruments supplier's stock worth $5,611,000 after acquiring an additional 112,851 shares during the period. AQR Capital Management LLC boosted its stake in OraSure Technologies by 48.3% in the 1st quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier's stock worth $3,511,000 after purchasing an additional 339,493 shares during the period. Empowered Funds LLC grew its holdings in OraSure Technologies by 7.2% during the 1st quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier's stock valued at $1,366,000 after buying an additional 27,310 shares in the last quarter. NewEdge Advisors LLC raised its position in shares of OraSure Technologies by 32,595.9% during the first quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier's stock valued at $161,000 after buying an additional 47,590 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its position in shares of OraSure Technologies by 32.7% during the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 8,133 shares during the last quarter. Hedge funds and other institutional investors own 93.50% of the company's stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.